Wu Vincent, Cusimano Michael D, Lee John M
From the Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, Ontario, Canada.
Am J Rhinol Allergy. 2018 Jan 1;32(1):52-56. doi: 10.2500/ajra.2018.32.4499.
Endoscopic transsphenoidal skull base surgery (ETSS) is now considered the criterion standard approach for resection of pituitary adenomas and other midline anterior skull base lesions. Normal sinonasal structures are resected during ETSS, which raises concerns for nasal morbidity and patient-based outcome.
To perform a surgical outcome assessment by examining whether the extent of ETSS approaches affected patient-specific sinonasal quality of life as measured by the 22-item Sino-Nasal Outcome Test (SNOT-22).
A single-center prospective cohort study of patients operated on by the same skull base team between 2012 and 2016. Patients with completed pre- and postoperative SNOT-22 were included. The primary outcome was SNOT-22 scores at preoperative, 0-1 month, 2-4 months, >5 months follow-up. Age, sex, tumor pathology, surgical procedure, and intraoperative cerebral spinal fluid leak repair were also obtained.
Of the 249 ETSS performed, 148 patients (59%) had at least one completed SNOT-22; 45 (18%) met the inclusion criteria. Sinonasal quality of life based on SNOT-22 at the 0-1-month follow-up was significantly worse than the presurgical levels (p < 0.05). However, there was a return of SNOT-22 scores to preoperative levels at 2-4 months (p > 0.05), which was sustained at >5 months (p > 0.05). Factors such as the extent of ETSS, a previous nasal surgery, repair of an intraoperative cerebral spinal fluid leak, and the tumor pathology did not affect SNOT-22 scores at any follow-up intervals (p > 0.05).
Sinonasal quality of life worsened after ETSS at 0-1 month follow-up but returned to preoperative levels at 2-4 months and remained at postoperative levels >5 months. Analysis of these data will allow us to educate our patients that the anticipated nasal morbidity after ETSS is usually only transient and should be expected to recover to preoperative levels.
内镜经蝶窦颅底手术(ETSS)目前被认为是切除垂体腺瘤和其他中线前颅底病变的标准方法。在ETSS手术过程中,正常的鼻窦结构会被切除,这引发了对鼻腔发病率和基于患者的治疗结果的担忧。
通过检查ETSS手术范围是否会影响患者特定的鼻窦生活质量(通过22项鼻窦结局测试(SNOT-22)来衡量)来进行手术结果评估。
对2012年至2016年间由同一颅底手术团队进行手术的患者进行单中心前瞻性队列研究。纳入术前和术后均完成SNOT-22评估的患者。主要结局指标为术前、术后0至1个月、2至4个月、随访超过5个月时的SNOT-22评分。还收集了患者的年龄性别、肿瘤病理、手术方式以及术中脑脊液漏修补情况等信息。
在249例ETSS手术中,148例患者(59%)至少完成了一次SNOT-22评估;45例(18%)符合纳入标准。在0至1个月的随访中,基于SNOT-22的鼻窦生活质量显著低于术前水平(p < 0.05)。然而,在2至4个月时SNOT-22评分恢复到术前水平(p > 0.05),并在随访超过5个月时保持这一水平(p > 0.05)。ETSS手术范围、既往鼻腔手术史、术中脑脊液漏修补情况以及肿瘤病理等因素在任何随访时间间隔均未影响SNOT-22评分(p > 0.05)。
ETSS术后0至1个月随访时鼻窦生活质量恶化,但在2至4个月时恢复到术前水平,并在随访超过5个月时维持术后水平。对这些数据的分析将使我们能够告知患者,ETSS术后预期的鼻腔发病率通常只是暂时的,有望恢复到术前水平。